The use of immune checkpoint inhibitors, which activate T cells, is a paradigm shift in the treatment of non–small cell lung cancer. However, the overall response remains low. To address this limitation, here we describe a novel platform, termed antibody-conjugated drug-loaded nanotherapeutics (ADN), which combines immunotherapy and molecularly targeted therapy. An ADN was designed with an anti-CD47 and anti–programmed death ligand 1 (PDL1) antibody pair on the surface of the nanoparticle and a molecularly targeted inhibitor of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway, PI103, entrapped in the nanoparticle. The anti–CD47-PDL1-ADN exhibited greater antitumor efficacy than current treatment options with a PDL1 inhibitor in vivo in an aggressive lung cancer immunocompetent mouse model. Dual antibody-drug–loaded nanotherapeutics can emerge as an attractive platform to improve outcomes with cancer immunotherapy.
The interaction of tumor cells with blood vessels is one of the key steps during cancer metastasis. Metastatic cancer cells exhibit phenotypic state changes during this interaction: (1) they form tunneling nanotubes (TNTs) with endothelial cells, which act as a conduit for intercellular communication; and (2) metastatic cancer cells change in order to acquire an elongated phenotype, instead of the classical cellular aggregates or mammosphere-like structures, which it forms in three-dimensional cultures. Here, we demonstrate mechanistically that a siRNA-based knockdown of the exocyst complex protein Sec3 inhibits TNT formation. Furthermore, a set of pharmacological inhibitors for Rho GTPase–exocyst complex-mediated cytoskeletal remodeling is introduced, which inhibits TNT formation, and induces the reversal of the more invasive phenotype of cancer cell (spindle-like) into a less invasive phenotype (cellular aggregates or mammosphere). Our results offer mechanistic insights into this nanoscale communication and shift of phenotypic state during cancer–endothelial interactions.
Trafficking of mitochondria from immune cells to cancer cells via physical nanotubes is a new mechanism by which cancer cells undergo immune evasion. This results in depletion of T cell, which can limit the efficacy of classical immune checkpoint inhibitors. Here we introduce a novel pharmacological inhibitor that inhibits nanotube-mediated mitochondria transfer from immune cell to cancer cell. Our preliminary study implicates the exocyst complex in the nanotube assembly. We performed molecular dynamic simulations to identify the potential inhibitors for the exocyst proteins. We have identified a drug candidate, TS-1, which successfully inhibits the mitochondria transfer from immune cell to cancer cell. Currently we are exploring the modification of the structural component to increase the inhibitory potential of the drug. TS-1-loaded liposome significantly inhibited tumor growth in a 4T1 metastatic breast cancer mouse model. We observed considerable increase in intratumoral T cell population with treatment. Furthermore, the use of TS-1 in combination with an anti-PD1 inhibitor resulted in effective tumor reduction in the 4T1 model, which typically responds poorly to anti-PD1 therapy alone. Conclusion: Taken together, the inhibition of nanotube-mediated mitochondrial hijacking from immune cells emerges as an approach for the development of next generation of immunotherapy agents. Citation Format: Tanmoy Saha, Ruparoshni Jaybalan, HaeLin Jang, Shiladitya Sengupta. A novel immunotherapy approach by inhibiting nanotube-mediated mitochondrial trafficking between cancer cells and T cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4238.